Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

By sjmartinez • October 25, 2023

Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Oct 19:S1470-2045(23)00515-6. doi: 10.1016/S1470-2045(23)00515-6. Epub ahead of print. PMID: 37875143.

Tags: Hematology/Oncology, Publications

Impact of Screening Mammography on Breast Cancer Outcomes in Women Aged 80 Years and Over

Huang SY, Murray M, Rubio A, Okoro N, Sedrak MS, McCloskey SA, Jackson N, Teshome M, Kapoor NS. Impact of Screening Mammography on Breast Cancer[...]

Identification of Targetable EGFR Mutations in Ovarian Cancer

Gower A, Win S, Ganguly R, Johnson M, Velez MA, Cummings AL, Lisberg A, Garon EB, Di Carlo B. Identification of Targetable EGFR Mutations in Ovarian Cancer.[...]

Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer

Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-Gonzalez A, Basar M, Gokturk Ozcan G, Teo MY,[...]